Abstract
Background
The present study aimed at (1) providing further validity and reliability evidence for the Italian version of the cognitive section of the ALS Cognitive Behavioral Screen (ALS-CBS™) and (2) testing its diagnostics within an Italian ALS cohort, as well as at (3) exploring its capability to discriminate patients from healthy controls (HCs).
Methods
N = 293 non-demented ALS patients were administered the cognitive sections of the ALS-CBS™ and Edinburgh Cognitive and Behavioural ALS Screen (ECAS). N = 96 HCs demographically matched with N = 96 patients were also administered the cognitive section of the ALS-CBS™. In patients, factorial and construct validity, internal reliability, and diagnostics against a defective score on the cognitive section of the ECAS were tested. Case–control discrimination was assessed via a logistic regression.
Results
ALS-CBS™ cognitive subscales were underpinned by a simple, unidimensional structure, internally reliable (McDonald’s ω = 0.74), and mostly related with ECAS executive and fluency scores (rs = 0.54–0.71). Both raw and age- and education-adjusted scores on the cognitive section of the ALS-CBS™ accurately detected ECAS-defined cognitive impairment (AUC = 0.80 and .88, respectively), yielding optimal error-based, information-based and unitary diagnostics. A cut-off of < 15.374 was identified on adjusted scores. The test was able to discriminate patients from HCs (p < 0.001).
Discussion
The cognitive section of the Italian ALS-CBS™ is a valid, reliable, and diagnostically sound ALS-specific screener for detecting frontotemporal, executive-/attentive-based cognitive inefficiency in non-demented ALS patients, being also able to discriminate them from normotypical individuals.
Similar content being viewed by others
Data availability
Datasets associated with the present study are available upon reasonable request of interested researchers.
References
Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, Turner MR (2017) Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 18:153–174
Huynh W, Ahmed R, Mahoney CJ, Nguyen C, Tu S, Caga J, Kiernan MC (2020) The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis. Expert Rev Neurother 20:281–293
Gray D, Abrahams S (2022) International evaluation of current practices in cognitive assessment for motor neurone disease. Br J Neurosci Nurs 18:38–44
Beswick E, Park E, Wong C, Mehta AR, Dakin R, Chandran S, Pal S (2021) A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis. J Neurol 268:4510–4521
Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, Katz JS (2010) Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS™). Amyotroph Lateral Scler 11:303–311
Abrahams S, Newton J, Niven E, Foley J, Bak TH (2014) Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 15:9–14
Simon N, Goldstein LH (2019) Screening for cognitive and behavioral change in amyotrophic lateral sclerosis/motor neuron disease: a systematic review of validated screening methods. Amyotroph Lateral Scler Frontotemporal Degener 20:1–11
Gosselt IK, Nijboer TC, Van Es MA (2020) An overview of screening instruments for cognition and behavior in patients with ALS: selecting the appropriate tool for clinical practice. Amyotroph Lateral Scler Frontotemporal Degener 21:324–336
Taule T, Søvik M, Lein RK, Wehling E, Aßmus J, Rekand T (2020) Psychometric properties of cognitive assessment in amyotrophic lateral sclerosis: a systematic review. Patient Relat Outcome Measures 11:181
Poletti B, Solca F, Carelli L, Madotto F, Lafronza A, Faini A, Silani V (2016) The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 17:489–498
Tremolizzo L, Lizio A, Santangelo G, Diamanti S, Lunetta C, Gerardi F, Appollonio I (2020) ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability. Neurol Sci 41:835–841
Siciliano M, Trojano L, Trojsi F, Greco R, Santoro M, Basile G, Santangelo G (2017) Edinburgh Cognitive and Behavioural ALS Screen (ECAS)-Italian version: regression based norms and equivalent scores. Neurol Sci 38:1059–1068
Poletti B, Solca F, Carelli L, Faini A, Madotto F, Lafronza A, Silani V (2018) Cognitive-behavioral longitudinal assessment in ALS: the Italian Edinburgh Cognitive and Behavioral ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 19:387–395
Aiello EN, Iazzolino B, Pain D, Peotta L, Palumbo F, Radici A, Chiò A (2022) The diagnostic value of the Italian version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 1–5.
Aiello EN, Solca F, Torre S, Carelli L, Monti A, Ferrucci R, Poletti B (2022) Reliable change indices for the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener 1–5.
Greco LC, Lizio A, Casiraghi J, Sansone VA, Tremolizzo L, Riva N, Lunetta C (2022) A preliminary comparison between ECAS and ALS-CBS in classifying cognitive–behavioural phenotypes in a cohort of non-demented amyotrophic lateral sclerosis patients. J Neurol 269:1899–1904
Aiello EN, Rimoldi S, Bolognini N, Appollonio IM, Arcara G (2022) Psychometrics and diagnostics of Italian cognitive screening test: a systematic review. Neurol Sci 43:821–845
Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Grossman M (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014
Poletti B, Aiello EN, Solca F, Torre S, Carelli L, Ferrucci R, Silani V (2022) Diagnostic properties of the Italian ECAS Carer Interview (ECAS-CI). Neurol Sci 1–6.
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, the BDNF Study Group (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169:13–21
Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, Hanafusa T (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66:265–267
Kim HY (2013) Statistical notes for clinical researchers: assessing normal distribution (2) using skewness and kurtosis. Restor Dent Endod 38:52–54
Hobart JC, Cano SJ, Warner TT, Thompson AJ (2012) What sample sizes for reliability and validity studies in neurology? J Neurol 259:2681–2694
Kyriazos TA (2018) Applied psychometrics: sample size and sample power considerations in factor analysis (EFA, CFA) and SEM in general. Psychology 9:2207
Larner AJ (2019) New unitary metrics for dementia test accuracy studies. Prog Neurol Psychiatry 23:21–25
Goksuluk D, Korkmaz S, Zararsiz G, Karaagaoglu AE (2016) easyROC: an interactive web-tool for ROC curve analysis using R language environment. The R Journal 8:213–230
Bossuyt PM (2010) Clinical validity: defining biomarker performance. Scand J Clin Lab Invest 70:46–52
Aiello EN, Esposito A, Giannone I, Diana L, Woolley S, Murphy J, ..., Appollonio I (2022d) ALS Cognitive Behavioral Screen-Phone Version (ALS-CBS™-PhV): norms, psychometrics, and diagnostics in an Italian population sample. Neurol Sci 43:2571-2578.
Cohen J (1988) Statistical power analysis for the behavioral sciences. Erlbaum
McMillan CT, Wuu J, Rascovsky K, Cosentino S, Grossman M, Elman L, Benatar M (2022) Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotroph Lateral Scler Frontotemporal Degener 1–10.
Acknowledgements
The authors are thankful to patients and their caregivers, as well as to healthy participants.
Funding
This research was funded by the Italian Ministry of Health to IRCCS Istituto Auxologico Italiano (Ricerca Corrente, project 23C302).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval and informed consent
Participants provided informed consent and data were treated according to current regulations. This study was approved by the Ethics Committee of IRCCS Istituto Auxologico Italiano (I.D.: 2013_06_25), by the Ethics Committee of Milano Niguarda Area 3 (I.D.: 393–09062021) and by the Ethics Committee of Istituti Clinici Scientifici Maugeri IRCCS (I.D.: CE 2495—12012021).
Conflict of interest
V. S. received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., and Novartis Pharma AG, receives or has received research supports from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. He is on the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology. B.P. and L.C. received compensation for consulting services and/or speaking activities from Liquidweb S.r.l. B.P is Associate Editor for Frontier in Neuroscience. N. T. received compensation for consulting services from Amylyx Pharmaceuticals and Zambon Biotech SA. He is Associate Editor for Frontiers in Aging Neuroscience. C.L. received compensation for consulting services and/or speaking activities from Cytokinetics, Italfarmaco, and Mitsubishi Tanabe Pharma Europe. He is Associate Editor for Frontiers in Neurology. V.A.S. participates in Advisory Boards or teaching activities for Biogen, Roche, Avexis, PTC, Santhera, Sarepta, Dyne. S.W. receives licensing fees when the ALS Cognitive Behavioural Screen (ALS-CBS™) is used in pharmaceutical trials. J.M. is employed full time at Biogen; she does not receive compensations related to the ALS-CBS™. The remaining authors have nothing to declare.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Aiello, E.N., Greco, L.C., La Tona, A. et al. Clinimetrics of the cognitive section of the Italian ALS Cognitive Behavioral Screen (ALS-CBS™). Neurol Sci 44, 1243–1249 (2023). https://doi.org/10.1007/s10072-022-06569-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-022-06569-9